AAAAAA

   
Results: 1-19 |
Results: 19
Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease
Authors: Aisen, PS Marin, DB Brickman, AM Santoro, J Fusco, M
Citation: Ps. Aisen et al., Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease, ALZ DIS A D, 15(2), 2001, pp. 96-101
Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death
Authors: Mukherjee, P Rachita, C Aisen, PS Pasinetti, GM
Citation: P. Mukherjee et al., Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death, CLIN EXP RH, 19(1), 2001, pp. S7-S11
Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarraytechnique
Authors: Ho, L Guo, YJ Spielman, L Petrescu, O Haroutunian, V Purohit, D Czernik, A Yemul, S Aisen, PS Mohs, R Pasinetti, GM
Citation: L. Ho et al., Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarraytechnique, NEUROSCI L, 298(3), 2001, pp. 191-194
Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease
Authors: Ho, L Purohit, D Haroutunian, V Luterman, JD Willis, F Naslund, J Buxbaum, JD Mohs, RC Aisen, PS Pasinetti, GM
Citation: L. Ho et al., Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease, ARCH NEUROL, 58(3), 2001, pp. 487-492
Elevated plasma neopterin levels in Alzheimer disease
Authors: Hull, M Pasinetti, GM Aisen, PS
Citation: M. Hull et al., Elevated plasma neopterin levels in Alzheimer disease, ALZ DIS A D, 14(4), 2000, pp. 228-230
Anti-inflammatory therapy for Alzheimer's disease - Commentary
Authors: Aisen, PS
Citation: Ps. Aisen, Anti-inflammatory therapy for Alzheimer's disease - Commentary, NEUROBIOL A, 21(3), 2000, pp. 447-448
A randomized controlled trial of prednisone in Alzheimer's disease - Reply
Authors: Aisen, PS Grundman, M Thomas, RG Thal, LJ
Citation: Ps. Aisen et al., A randomized controlled trial of prednisone in Alzheimer's disease - Reply, NEUROLOGY, 55(7), 2000, pp. 1067-1067
Elevated CSF prostaglandin E-2 levels in patients with probable
Authors: Ho, L Luterman, JD Aisen, PS Pasinetti, GM
Citation: L. Ho et al., Elevated CSF prostaglandin E-2 levels in patients with probable, NEUROLOGY, 55(2), 2000, pp. 323-323
A randomized controlled trial of prednisone in Alzheimer's disease
Authors: Aisen, PS Davis, KL Berg, JD Schafer, K Campbell, K Thomas, RG Weiner, MF Farlow, MR Sano, M Grundman, M Thal, LJ
Citation: Ps. Aisen et al., A randomized controlled trial of prednisone in Alzheimer's disease, NEUROLOGY, 54(3), 2000, pp. 588-593
Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia
Authors: Luterman, JD Haroutunian, V Yemul, S Purohit, D Aisen, PS Mohs, R Pasinetti, GM
Citation: Jd. Luterman et al., Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia, ARCH NEUROL, 57(8), 2000, pp. 1153-1160
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease
Authors: Mehta, PD Pirttila, T Mehta, SP Sersen, EA Aisen, PS Wisniewski, HM
Citation: Pd. Mehta et al., Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease, ARCH NEUROL, 57(1), 2000, pp. 100-105
Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial
Authors: Aisen, PS
Citation: Ps. Aisen, Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial, ACT NEUR SC, 102, 2000, pp. 85-89
Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity
Authors: Osaka, H Mukherjee, P Aisen, PS Pasinetti, GM
Citation: H. Osaka et al., Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity, J CELL BIOC, 73(3), 1999, pp. 303-311
Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease
Authors: Ho, L Pieroni, C Winger, D Purohit, DP Aisen, PS Pasinetti, GM
Citation: L. Ho et al., Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease, J NEUROSC R, 57(3), 1999, pp. 295-303
Increased levels of tau-like protein in patients with Down syndrome
Authors: Mehta, PD Patrick, BA Dalton, AJ Aisen, PS Emmerling, ME Sersen, EA Wisniewski, HM
Citation: Pd. Mehta et al., Increased levels of tau-like protein in patients with Down syndrome, NEUROSCI L, 275(3), 1999, pp. 159-162
Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2
Authors: Kelley, KA Ho, L Winger, D Freire-Moar, J Borelli, CB Aisen, PS Pasinetti, GM
Citation: Ka. Kelley et al., Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2, AM J PATH, 155(3), 1999, pp. 995-1004
Anti-inflammatory drug studies in Alzheimer's disease
Authors: Aisen, PS
Citation: Ps. Aisen, Anti-inflammatory drug studies in Alzheimer's disease, RESEARCH AND PRACTICE IN ALZHEIMER'S DISEASE, VOL 2, 1999, pp. 299-302
Immunophilin-binding drugs inhibit amyloid beta-peptide mediated impairment of redox activity
Authors: Osaka, H Aisen, PS Pasinetti, GM
Citation: H. Osaka et al., Immunophilin-binding drugs inhibit amyloid beta-peptide mediated impairment of redox activity, ALZHEIM REP, 1(3), 1998, pp. 155-158
HLA-DR4 influences glial activity in Alzheimer's disease hippocampus
Authors: Aisen, PS Luddy, A Durner, M Reinhard, JF Pasinetti, GM
Citation: Ps. Aisen et al., HLA-DR4 influences glial activity in Alzheimer's disease hippocampus, J NEUR SCI, 161(1), 1998, pp. 66-69
Risultati: 1-19 |